Navigation Links
Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
Date:7/21/2008

NEW YORK, July 21 /PRNewswire/ -- Ari Kiev, M.D., president of SPRI Clinical Trials, will be a featured speaker at the upcoming conference Wall Street Unplugged: The Trout Group Investor Seminar -- Management's Guide to Wall Street. The conference will be held on Wednesday, July 30, at Midtown Loft & Terrace, 267 Fifth Avenue in New York. The event is targeted to CEOs and CFOs at private and small and mid-cap life science companies to gain better insight into Wall Street and maximize communication with the investment community.

Dr. Kiev, a peak performance strategist and author of six books on trading psychology, will speak on "Risk-Reward and Valuation of Clinical Stage Compounds: Challenge Your Perspective." His presentation will cover investors' perceptions of early stage companies, advising biotech CEOs on the most effective ways to position clinical trial data to help achieve an optimum valuation.

"Biotech CEOs should challenge their perspectives on the industry and try to see valuation from an investor's point of view rather than that of a scientist," Dr. Kiev said. "There tends to be too much emphasis on hyperbole as to the novelty of the mechanism and the size of the market. Focusing too much on why the stock is going up or down can turn off investors who are looking for greater involvement by the company in the path to success in clinical trials."

Dr. Kiev founded SPRI (http://www.spriclinicaltrials.com) in 1970 to provide top rate clinical trial services to the pharmaceutical and biotech industry. With nearly 40 years of experience managing studies in the New York area, SPRI expanded internationally in 2003. Today, the company conducts studies throughout Eastern and Western Europe.


'/>"/>
SOURCE SPRI Clinical Trials
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
2. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
4. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
8. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
9. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... ROCKY HILL, Conn. , June 18, 2013 ... many past clients of Alliance Seating and Mobility, ... now unable to access timely repair. This appears ... and a dramatic reduction of field service employees.  ... Unfortunately a great many of these clients ...
(Date:6/18/2013)... , June 18, 2013  Cataracts are the leading ... American Association of Ophthalmology, aging is the leading cause ... the eye,s natural lens. 22 million Americans age 40 ... Boomers continue to age, that number will increase over ... of iPhones, iPads, smart-phones and computers, the demographic of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... (NYSE: LLY ) will present data from more ... American Society of Clinical Oncology (ASCO) in Chicago, Ill., from ... Phase III study of an ALIMTA-based continuation maintenance regimen for ... data will be included in the ASCO-sponsored press briefing the ...
... Systems Inc. (OTCBB: PLCSF), a company focused on innovative ... three- month period ended March 31, 2011. These results ... the sale of its transmyocardial revascularization (TMR) business to ... from the TMR business for the first quarter of ...
Cached Medicine Technology:Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO 2PLC Systems Reports First Quarter 2011 Results 2PLC Systems Reports First Quarter 2011 Results 3PLC Systems Reports First Quarter 2011 Results 4PLC Systems Reports First Quarter 2011 Results 5PLC Systems Reports First Quarter 2011 Results 6PLC Systems Reports First Quarter 2011 Results 7
(Date:6/18/2013)... 2013 The Drug Delivery Partnering Terms ... to the drug delivery partnering deals and agreements entered ... The report provides a detailed understanding and analysis of ... The majority of deals are discovery or development stage ... right to license the license drug delivery technology. These ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Senior drug regulatory ... on June 25 to discuss—for the first time in the ... getting drugs through the regulatory process in a timely manner. ... evaluation will share respective best practices and processes in drug ... Strait panel at the DIA 2013 49th Annual ...
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... Dallas, TX (PRWEB) June 18, 2013 ... Tebbetts, launched his new website, thebestbreast.com, showcasing his ... provides women with information about his surgical method ... , Outlined on his website, Dr. Tebbetts ... Unlike the traditional methods, Dr. Tebbetts’ method does ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
Breaking Medicine News(10 mins):Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:SimuCase avatars advance speech-language pathology training 2
... RATON, Fla., Sept. 26 Biomedtex Inc.,(Pink Sheets: ... company, announced today that A. Marc Rocca, 42, ... The Company,s mission is to identify, evaluate ... and healthcare solutions, and then,seek to capture and ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... North America in Deal Valued at up ... to $185 ... 26, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) and,Nycomed announced ... to Nycomed the rights to develop and commercialize,GATTEX(TM) (teduglutide) outside ...
... ultrasound-guided fine needle to biopsy lymph nodes could spare ... to undergo unnecessary and sometimes unpleasant surgery to verify ... , In a study presented today (Wednesday) at the ... that the less invasive technique produced a false positive ...
... Barcelona, Spain: New research has yielded a clearer picture ... the treatment of colon cancer, bringing closer the day ... spared it, while those that will, get the more ... other solid tumours, doctors plan treatment of colon cancer ...
... to use for older people is the focus of a ... in funding in the latest round of the Australian Research ... design researcher Dr Thea Blackler, is one of 24 projects ... announcement tops off a successful week for QUT research, with ...
Cached Medicine News:Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: